RECRUITING

The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality

Description

The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies. The main questions it aims to answer are: * Does GLP-1 and GIP agonist increase the rate of inadequate bowel preparation? * Does the quality of bowel preparation differ in patients who hold vs. those who continue a single dose of their GLP-1 or GIP agonist medication? * Are there any differences in the rates of complications gastric aspiration in patients who hold vs. continue a single dose of their GLP-1 or GIP agonist medication?

Conditions

GLP - 1Bowel Preparation for Colonoscopy
Talk to us

Related Conditions:

GLP - 1Bowel Preparation for Colonoscopy

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies. The main questions it aims to answer are: * Does GLP-1 and GIP agonist increase the rate of inadequate bowel preparation? * Does the quality of bowel preparation differ in patients who hold vs. those who continue a single dose of their GLP-1 or GIP agonist medication? * Are there any differences in the rates of complications gastric aspiration in patients who hold vs. continue a single dose of their GLP-1 or GIP agonist medication?

The Impact of GLP-1 Agonist and GIP Agonist on Bowel Preparation Quality: A Randomized Controlled Trial

The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality

Condition
GLP - 1
Intervention / Treatment

-

Contacts and Locations

Cleveland

Cleveland Clinic, Cleveland, Florida, United States, 44195

Weston

Cleveland Clinic Weston, Weston, Florida, United States, 33331

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult patient (Age 18 years or older)
  • * Patient scheduled for outpatient screening, surveillance, or diagnostic colonoscopy
  • * Using a GLP-1 or GIP agonist at a stable dose for at least one month
  • * Unable to provide informed consent, e.g., dementia
  • * Patient refuses the USMSTF recommended bowel cleansing regimen for patients with diabetes or obesity (split-dose 4 liters polyethylene glycol + 15 mg bisacodyl the afternoon before; low residue diet 3 days before colonoscopy; clear liquid diet the day before colonoscopy)
  • * Risk factors for inadequate bowel preparation besides diabetes and obesity with a likelihood ratio of 1.6 or greater:
  • 1. Cirrhosis
  • 2. Parkinson's disease
  • 3. Dementia
  • 4. Tricyclic antidepressant use
  • 5. Opioid use
  • 6. Gastroparesis\* or suspected gastric outlet obstruction on pre-procedure imaging (\*defined based on a documented 4-hour solid phase gastric emptying study or prior history of retained gastric contents during upper endoscopy)
  • 7. Previous colorectal surgery
  • 8. Prior history of inadequate bowel preparation

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

The Cleveland Clinic,

Study Record Dates

2026-08